Blog
RSS FeedPosted by Michael Wonder on 15 Jun 2022
Shionogi signs agreement with NHS England to begin an innovative subscription payment model for reimbursement of its antibiotic, Fetcroja (cefiderocol)
15 June 2022 - Shionogi recognises the UK’s leadership role in introducing the world’s first fully ‘delinked’ pilot reimbursement model; pull ...
Posted by Michael Wonder on 15 Jun 2022
England’s Innovative Medicines Fund hits another milestone
15 June 2022 - Just like the Cancer Drugs Fund, the time-limited fund for the most promising cancer drugs introduced ...
Posted by Michael Wonder on 07 Jun 2022
Trends in prescription drug launch prices (2008-2021)
7 June 2022 - Prescription drug spending in the US exceeded half a trillion dollars in 2020. ...
Posted by Michael Wonder on 09 May 2022
The Center for Medicare and Medicaid Innovation - toward value based care
9 May 2022 - Before the enactment of the Patient Protection and Affordable Care Act in 2010, experimentation with Medicare or ...
Posted by Michael Wonder on 08 May 2022
Supporting innovation in Medicaid policy - interventions to increase adoption of RCTs
7 May 2022 - Randomised, controlled trials remain underutilised within the Medicaid program, even though state Medicaid programs regularly implement new ...
Posted by Michael Wonder on 21 Apr 2022
Are high cost prescription drugs the price of innovation? Disclose the costs of clinical trials.
21 April 2022 - With 40% of Americans struggling to afford prescription medicines and many rationing or delaying initiation of lifesaving ...
Posted by Michael Wonder on 29 Mar 2022
Nurix Therapeutics awarded Innovation Passport for entry into Innovative Licensing and Access Pathway in the United Kingdom for NX-1607
29 March 2022 - NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumour types. ...
Posted by Michael Wonder on 03 Mar 2022
PRIME enables earlier availability of life-changing medicines
3 March 2022 - EMA’s PRIority Medicines (PRIME) scheme has had a positive impact on the authorisation of new medicines that ...
Posted by Michael Wonder on 19 Feb 2022
How digital therapeutics platforms are revolutionising health care delivery
17 February 2022 - With enormous advances in digital health innovation, we are quickly moving into an age where software platforms ...
Posted by Michael Wonder on 15 Feb 2022
MTAA welcomes patent box legislation
11 February 2022 - MTAA has welcomed the introduction of the Government’s Patent Box Bill into the House of Representatives ...
Posted by Michael Wonder on 10 Feb 2022
Patent box legislation to promote Australian innovation
11 February 2022 - Medicines Australia notes the introduction of patent box legislation, Treasury Laws Amendment (Tax Concession for Australian ...
Posted by Michael Wonder on 10 Feb 2022
Theragnostics announces that its radiotherapeutic for treatment of glioblastoma multiforme has been awarded UK's MHRA innovation passport
10 February 2022 - Promising non-clinical results support Phase 1 clinical study in recurrent glioblastoma multiforme. ...
Posted by Michael Wonder on 08 Dec 2021
Don’t destroy future drug development
8 December 2021 - With support faltering for the massive big-government blowout Congress is trying to jam through by Christmas, ...
Posted by Michael Wonder on 08 Dec 2021
New therapies for a range of conditions are coming in 2022
8 December 2021 - Haemophilia, brain disorders and malaria are being targeted. ...
Posted by Michael Wonder on 15 Nov 2021
Competing with, and learning from, China in the global pharmaceutical innovation race
15 November 2021 - President Joe Biden has promoted investment in technology based industries, including the life sciences, as a strategic ...